Tech Company M&A Transactions
Cardioxyl Pharmaceuticals Acquisition
Headquartered in Chapel Hill, Cardioxyl Pharmaceuticals was acquired by Bristol-Meyers Squibb. The transaction price was $2.1 billion.
Transaction Overview
Company Name
Acquired By
Announced On
11/2/2015
Transaction Type
M&A
Amount
$2,075,000,000
M&A Terms
The transaction includes upfront and near-term milestone payments of up to $300 million and potential additional consideration of up to $1.775 billion upon the achievement of certain development, regulatory and sales milestones.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
1450 Raleigh Rd. 212
Chapel Hill, NC 27517
USA
Chapel Hill, NC 27517
USA
Phone
Website
Email Address
Overview
Cardioxyl Pharmaceuticals' mission is the discovery and development of newclasses of safe and effective therapeutic agents for the treatment ofcardiovascular disease. Cardioxyl's initial program is a novel medication forthe treatment of acute decompensated heart failure.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Christopher Kroeger
Chief Medical Officer
Shi Foo
Chief Scientific Officer
John Reardon
VP - Regulatory Affairs
Doug Cowart
Browse more venture capital transactions:
Prev: 11/2/2015: Knewton venture capital transaction
Next: 11/2/2015: Confer venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on all VC transactions involving tech companies. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs